Latest Developments in Cellular Therapy for Multiple Myeloma

Tara K Gregory; Henning Schade; Jesús G Berdeja

doi:10.17925/OHR.2021.16.2.111

Latest Developments in Cellular Therapy for Multiple Myeloma

Tara K Gregory
, Henning Schade
, Jesús G Berdeja

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Oncology & Hematology Review
Volume	16
Issue number	2
DOIs	https://doi.org/10.17925/OHR.2021.16.2.111
State	Published - Jan 1 2021

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.17925/OHR.2021.16.2.111License: Unspecified

Cite this

@article{f97f06aa7f37488ea9e8b36dadeade7a,

title = "Latest Developments in Cellular Therapy for Multiple Myeloma",

author = "Gregory, \{Tara K\} and Henning Schade and Berdeja, \{Jes{\'u}s G\}",

note = "Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable [...]",

year = "2021",

month = jan,

day = "1",

doi = "10.17925/OHR.2021.16.2.111",

language = "American English",

volume = "16",

journal = "Oncology \& Hematology Review",

number = "2",

}

TY - JOUR

T1 - Latest Developments in Cellular Therapy for Multiple Myeloma

AU - Gregory, Tara K

AU - Schade, Henning

AU - Berdeja, Jesús G

N1 - Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable [...]

PY - 2021/1/1

Y1 - 2021/1/1

UR - http://dx.doi.org/10.17925/ohr.2021.16.2.111

U2 - 10.17925/OHR.2021.16.2.111

DO - 10.17925/OHR.2021.16.2.111

M3 - Article

VL - 16

JO - Oncology & Hematology Review

JF - Oncology & Hematology Review

IS - 2

ER -

Latest Developments in Cellular Therapy for Multiple Myeloma

Disciplines

Access to Document

Other files and links

Cite this